Seagen and Astellas announce results from EV-302 study
Trial involves the use of Padcev and Keytruda among patients with certain types of urothelial cancer
Read More
Tag: Seagen
EMA accepts Astellas/Seagen’s enfortumab vedotin for review
Marketing authorisation application is seeking approval for advanced urothelial cancer
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
